OneSkin launches topical senetherapeutic skin treatment

Extending skinspan with non-invasive senetherapeutic proprietary peptide.

OneSkin is a Longevity company on a mission to transform the way we think about skin. Today the company is launching OneSkin, a topical supplement containing a proprietary peptide, OS-01. Designed to reduce skin’s biological age, OneSkin claims to improve the skin barrier, support DNA damage repair and prevent the accumulation of senescent cells.

Longevity.Technology: By tackling senescent skin cells and halting the production of their associated toxic chemical secretions, OneSkin’s patented anti-senescent compound OS-1 is slated to reduce the molecular age of skin cells. The reduction of senescence-linked inflammation is a possible therapeutic indication for Longevity. 

OneSkin launched in 2016 as a biotech startup after acceptance into IndieBio, one of the world’s leading science accelerators. The team is led and co-founded by Carolina Reis, Alessandra Zonari, Mariana Boroni, Juliana Carvalho and includes Senior Scientist, Lear Brace, a Harvard PhD and Postdoctoral Fellow at the Buck Institute for Research on Aging and Peter Diamandis as one of its advisors.

Raising just over $2 million in 2017, OneSkin counted IndieBio, 2Future Holding and SOSV Ventures as its first investors for its seed round. Following a $3.5 million post-seed round in July 2019 from several angel investors, the most recent funding round was July 2020, with an angel investment of $1.5 million.



“… We saw a need to shift the current paradigm. Instead of short-term fixes that focus purely on aesthetics, we’re targeting the root cause of aging and optimizing skin health on a molecular level.”



“Our goal was to develop a product that extends skinspan, the period of time your skin is healthy and youthful,” said Carolina Reis, Co-founder and CEO at OneSkin. “Our roots are in longevity science and we saw a need to shift the current paradigm. Instead of short-term fixes that focus purely on aesthetics, we’re targeting the root cause of aging and optimizing skin health on a molecular level. We believe what we put on our skin should be safe, effective, and help to maximize our human potential.”

OneSkin operates end-to-end R&D in-house with a team of experts in stem cell biology, skin regeneration, tissue engineering, biochemistry, bioinformatics, molecular biology, immunology and aging. They measure skinspan in with MolClock – OneSkin’s first skin-specific molecular clock – and with skin aging modelling, using a proprietary technology and lab process which includes growing 3D human skin weekly and measuring how various products and ingredients influence gene expression of the many genes associated with aging and Longevity.

First Longevity

OneSkin’s senetherapeutic proprietary peptide product OS-01

The OneSkin team use MolClock to understand how the proprietary OS-01 peptide affects skin at a molecular level and measure actual rejuvenation potential. The clock is also used to appreciate the full efficacy of different products, including how products influence gene and protein expression, skin barrier, and skin structure, with the aim of ensuring the topical skin supplement is as effective as possible at promoting long term skin health.

“As we age, senescent cells begin to accumulate in our skin tissues. The accumulation of these cells can contribute to an increased presence of wrinkles, susceptibility to skin cancer, and a damaged skin barrier,” said Alessandra Zonari, Co-founder and Chief Scientific Officer at OneSkin. “Beyond its impact on skin, when left to linger, senescent cells send pro-inflammatory signals to the rest of the body, increasing the risk of age-related

OneSkin’s proprietary peptide OS-01 has been designed to optimise two key areas. It improves the health of the skin by improving the skin barrier, supporting DNA damage repair, and preventing the accumulation of senescent cells. This reduces skin’s biological age, as well as leading to increased epidermal thickness, improved skin structure through increased collagen production and hyaluronic express, maintained skin homeostasis and cell vitality.

OS-01 also works on skin health, optimising the molecular health of skin to improve its external strength; this results in firmer, smoother, more hydrated skin with decreased inflammation, fewer fine lines and wrinkles, decreased dark spots, and skin with an improved overall appearance.

First Longevity
Images courtesy of OneSkin


Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Latest articles

Neurotech2020 – a clear head for neurotech, research and investment

Tomorrow's dreams today ... well, next week – it's Neurotech2020. Neurotech2020 – the digital congress for neurotechnology innovation and growth – is coming to (your...

Biotech Elevian announces $15m equity financing

The anti-aging company looks to the clinic with Prime Movers Lab leading the round. Massachusets-based Elevian announced this week that it had closed $15 million equity...

eGenesis advances xenotransplantation research

Reducing waiting lists and treating diabetes – eGenesis progresses xeno without the paradox. Recently we covered eGenesis' progress in its xenotransplantation research, as it attempts...

Review: WHOOP fitness tracker

We trialled this beautifully-understated fitness/sleep tracking device to see if it would make us whoop with joy or holler for something else.   GO LONG    GO...